Prithviraj Bose, MD, discusses differences in the safety profiles of ruxolitinib and fedratinib in the treatment of myelofibrosis.
Prithviraj Bose, MD, associate professor, The University of Texas MD Anderson Cancer Center, discusses differences in the safety profiles of ruxolitinib (Jakafi) and fedratinib (Inrebic) in the treatment of myelofibrosis.
Bose believes ruxolitinib and fedratinib are similar in terms of efficacy and toxicity. Looking at ruxolitinib in the COMFORT trial and fedratinib in the JAKARTA trial, the rate of spleen volume reduction, total symptom score reduction and the incidence of the main adverse events, including anemia, and thrombocytopenia, are comparable, according to Bose.
Darolutamide Becomes Routine Doublet and Triplet Option in Hormone-Sensitive Prostate Cancer
May 6th 2024Darolutamide has been adopted routinely in clinical practice as a component of both doublet and triplet regimens for the treatment of patients with metastatic hormone-sensitive prostate cancer.
Read More
Responders to UGN-101 Have Positive RFS in Upper Tract Urothelial Cancer
May 5th 2024In patients at 15 centers who had upper tract urothelial cancer, those with no evidence of disease after UGN-101 induction had a 68% rate of 3-year recurrence-free survival, and this outcome did not differ based on tumor status, method of instillation, or treatment intent.
Read More